Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART.
Naidoo K. et al, (2025), South Afr J HIV Med, 26
Improving the quality of interpersonal care in HIV programmes
Tlhaku K. and Dorward J., (2024), Lancet HIV
High burden of Human Papillomavirus and pre-malignant cervical lesions among women starting HIV treatment in KwaZulu-Natal, South Africa
Naicker N. et al, (2024), Sexually Transmitted Infections
Healthcare worker perspectives on adaptations to differentiated anti-retroviral therapy delivery during COVID-19 in South Africa: A qualitative inquiry
Tlhaku K. et al, (2024), PLOS Global Public Health, 4
Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
Dorward J. et al, (2024), J Acquir Immune Defic Syndr, 95, e8 - e11
Early HIV viral suppression associated with subsequent 12‐month treatment success among people living with HIV in South Africa
Violette LR. et al, (2024), HIV Medicine
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Standing JF. et al, (2024), Nature Communications, 15
Changes in the medical admissions and mortality amongst children in four South African hospitals following the COVID-19 pandemic: A five-year review.
Naidoo KL. et al, (2024), PLOS Glob Public Health, 4
Intimate Partner Violence and HIV Outcomes Among Women Living with HIV in Durban, South Africa
Ojeaburu SO. et al, (2024), AIDS and Behavior
Risk of major cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: retrospective cohort analyses using routine, de-identified data from South Africa
Dorward J. et al, (2024), JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 27, 20 - 20
Tenofovir-diphosphate concentrations and viral suppression following monthly point-of-care urine tenofovir testing among adults initiating antiretroviral therapy: primary outcome of the randomised controlled STREAM HIV trial
Garrett N. et al, (2024), JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 27, 105 - 106